Last refreshed: September 4, 2026 (US ET)
Back to holdings

RVTY

Growth

Revvity, Inc.

Health Care·Diagnostics & Research·β 1.13Yield: Low (<1%)

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.

Close · 3M

+19.64%

RVTY · 3M

+19.64%

Pinch / wheel to zoom · drag to pan · double-tap to reset

Held by 0 AI ETFs

None of the tracked AI ETFs currently hold this name.

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals1
Win rate100% (1/1)
Avg buy return+3.54%
AIEQno longer held3 signals

AIEQ · Exit · 1d

weight 0.090% → 0 (exited)·stock down 0.3% in the 30 days before

Aug 2·entry $115.22·now $116.84

+1.41%
since Aug 2

AIEQ · New entry · 1d

weight 0 → 0.090% (new)·stock up 21.6% in the 30 days before

Jul 1·entry $112.84·now $116.84Drifting

+3.54%
since Jul 1

AIEQ · Exit · 1d

weight 0.190% → 0 (exited)·stock down 1.3% in the 30 days before

May 3·entry $86.51·now $116.84

+35.06%
since May 3

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of May 4

The AI ETF AIEQ's recent exit from Revvity aligns with this framework's 'Fail' verdict. The AI's decision to liquidate its position suggests a lack of conviction, potentially reflecting concerns about the company's financial health or valuation, which are also the primary reasons for the framework's negative assessment.

  • Circle of CompetenceThe company's diversified operations in diagnostics and research provide a stable base for projecting unit economics over a ten-year horizon, despite industry complexity.
  • Economic MoatRevvity likely benefits from switching costs associated with its specialized lab equipment and software, along with a strong brand reputation in the diagnostics and research sectors.
  • ManagementThe provided financial data does not offer sufficient information to assess management's candor, capital allocation discipline, or ownership stakes.
  • Financial HealthThe company's recent Return on Equity (ROE) of 3.24% falls far short of the required 10-15% range, indicating a clear failure in financial health according to the framework.
  • Margin of SafetyWith a P/E ratio of 40.18 and EV/EBITDA of 23.54, combined with low revenue growth and poor ROE, the current price does not offer a defensible margin of safety relative to intrinsic value.

Revvity passes the circle of competence and economic moat criteria, suggesting a predictable business with durable competitive advantages. However, it significantly fails on financial health due to a very low Return on Equity and also on margin of safety, trading at high valuation multiples despite its current financial performance. Therefore, a Buffett-style analysis would classify Revvity as a 'Fail' due to its current financial metrics and unattractive valuation.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.